Dublin, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/6kftxz/north_american)
has announced the addition of the "North
American Nuclear Medicine/Radiopharmaceuticals & Stable
Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)],
[Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications
(Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to
2017" report to their offering.
The North American radiopharmaceuticals market was valued at $1.9
billion in 2012 and is poised to reach $2.7 billion by 2017 at a
CAGR of 7.2%.
A study conducted by Organization for Economic Co-operation and
Development (OECD) estimates that Tc-99m diagnostic procedures are
expected to increase by 15% to 20% in mature markets such as North
America between 2010 and 2030. Radiopharmaceuticals in neurological
applications such as Alzheimer's disease, Parkinson's disease, and
dementia are also being preferred by practitioners besides
conventional treatment. Further, upcoming radioisotopes such as
Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical
applications. The scheduled shutdown of the NRU reactor in 2016 in
Canada is, however, a major threat for manufacturers.
The therapy market is predominantly driven by its oncologic
applications. Since conventional treatment procedures of cancer,
surgery and chemotherapy have significant side effects;
radioisotopes are being preferred by medical practitioners due to
minimum or no side effects. The radiopharmaceutical therapy market
is expected to grow significantly with the launch of the
much-desired Alpharadin (Ra-223) in the near future. This isotope
has tremendous potential to take up market share of beta emitters
and brachytherapy.
The U.S. is the dominant market for diagnostic radioisotopes with
more than 80% share. The U.S. is the largest consumer market for
radiopharmaceuticals
in North America, while Canada is one of the largest producers of
Tc-99m. Major players in the radiopharmaceuticals market are
Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc.
(U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc.
(U.S.).
The stable isotopes market was led by two players - Cambridge
Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they
jointly contributed more than 90% to the North American
revenue.
Key Topics Covered:
1 Introduction
2 Executive Summary
3 Market Overview
4 North American Radiopharmaceuticals Market, By Isotope
5 North American Radiopharmaceuticals Market, By
Application/Indications
6 North American Enriched Stable Isotopes Market
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles
Companies Mentioned
- Australian Nuclear Association And Technology Organization (Ansto)
- Board Of Radiation And Isotope Technology (Brit)
- Bracco Imaging S.P.A.
- Cambridge Isotope Laboratories, Inc.
- Cardinal Health, Inc.
- Covidien, Plc
- Eczacibasi-Monrol
- Fujifilm Holdings Corporation
- Ge Healthcare (Subsidiary Of General Electric Company)
- Iba Group
- Institute Of Atomic Energy Polatom Radioisotope Centre
- Institute Of Isotopes Co., Ltd.
- Institute Of Radioelement (Ire)
- Isotec, Inc. (Sigma-Aldrich)
- Lantheus Medical Imaging, Inc.
- Nordion, Inc.
- Ntp Radioisotopes (Pty), Ltd.
- Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
- Rotem Industries, Ltd., Inc.
- Taiyo Nippon Sanso Corporation
- Triad Isotopes, Inc.
- Urenco Limited
For more information visit http://www.researchandmarkets.com/research/6kftxz/north_american
About Research and Markets
Research and Markets is the world's leading source for
international market research reports and market data. We provide
you with the latest data on international and regional markets, key
industries, the top companies, new products and the latest
trends.
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals